INTRODUCTION
Calreticulin is a calcium-binding protein mainly present in the lumen of the endoplasmic reticulum of the cell that also has functions in other cellular compartments (1). Calreticulin's cytoplasmic role was shown in fibroblasts from mice with homozygous deletions in the calreticulin gene (2) . These mice had defects in integrin-mediated cell adhesion to extracellular matrix as well as the transient elevation in cytoplasmic calcium after integrin engagement (2) . This cytoplasmic function is related to calreticulin's interaction with the conserved amino acid sequence KLGFFKR found in the ␣-subunit of integrins (3, 4) . Calreticulin may also have a nuclear function in that it modulates transcriptional activity of steroid hormone nuclear receptors (5, 6) . It binds the same conserved protein motif KXFF(K/R)R found in the DNA-binding domain of nuclear hormone receptors of sterol hormones. In this way it prevents them from interacting with their DNA-responsive elements. There is recent evidence that the nuclear function may be dependent upon a calreticulin-dependent signaling from the endoplasmic reticulum (7) , in addition to the sterol hormone-dependent enhanced nuclear localization of calreticulin (8) . Calreticulin inhibited glucocorticoidand androgen-mediated gene transcription (5, 6) . In addition, it prevented the binding and action of 1,25-dihydroxyvitamin D 3 [1,25-(OH) 2 D 3 ] on the osteopontin gene in vitro (9) .
The chicken PTH vitamin D 3 response element (cPTH VDRE) is located between Ϫ74 and Ϫ60 of the cPTH gene 5Ј-flanking region. It is composed of two imperfect direct repeats, GGGTCA and GGGTGT, that are separated by a 3-bp interval (10) . Vitamin D receptor (VDR) binds to this responsive element primarily as a heterodimer, in the presence of retinoid X receptor-␤ (RXR␤) (10) . In the rat PTH promoter there are two VDREs, of different affinities (11) . The rat high PTH high-affinity VDRE (VDRE1) is located at Ϫ793 to Ϫ779 and is GGTTCA GTG AGGTAC (11) . In transfection experiments the two negative VDREs were required for maximal inhibition of CAT transcription by 1,25-(OH) 2 D 3 (11) . In bovine parathyroid cells there is an additive response of retinoic acid with 1,25-(OH) 2 D 3 to decrease PTH mRNA levels (12) . In addition, Farrow and co-workers (13, 14) have identified DNA sequences upstream of the bovine PTH gene that bind the 1,25-(OH) 2 D 3 receptor. Demay et al. (15) identified DNA sequences in the human PTH gene that bound the 1,25-(OH) 2 D 3 receptor. When placed upstream to a heterologous viral promoter, the sequences contained in this 25-bp oligonucleotide mediated transcriptional repression in response to 1,25-(OH) 2 D 3 in GH4C1 cells but not in ROS 17/2.8 cells. The downregulatory element in the PTH promoter differs from up-regulatory elements both in sequence composition and in the requirement for particular cellular factors other than the VDR for repressing PTH transcription (15) (16) (17) . The transcription of the PTH gene is markedly decreased by 1,25-(OH) 2 D 3 both in vitro (18, 19) and in vivo (20, 21) . This effect of 1,25-(OH) 2 D 3 is used clinically in patients with chronic renal failure to decrease the synthesis and secretion of PTH (22, 23) .
Therefore, the regulation of PTH gene transcription is relevant not only in understanding the physiology of the parathyroid gland, but also in the pathophysiology of diseases involving the parathyroid in which there is parathyroid hyperplasia such as chronic renal failure. There are many patients (Ͼ40% in some series) with chronic renal failure in whom administration of 1,25-(OH) 2 D 3 does not decrease serum PTH levels (24) . This may be related to a number of factors, such as decreased parathyroid levels of the VDR (25) and the calcium-sensing receptor (26) (27) (28) , monoclonality of the parathyroid hyperplasia (29) 
RESULTS AND DISCUSSION

Hypocalcemia Increases Calreticulin Protein in the Parathyroid
Weanling rats were fed a low-calcium diet for 2 weeks. This led to a marked hypocalcemia (6.5 Ϯ 0.6: 11 Ϯ 1.1 mg/dl (n ϭ 4); P Ͻ 0.01) and increased serum 1,25-(OH) 2 D 3 levels (845 Ϯ 56: 145 Ϯ 26 pg/ml; P Ͻ 0.01) as compared with controls. There was a marked increase in PTH mRNA levels in these hypocalcemic rats (Fig. 1A ) despite the increased levels of endogenous 1,25-(OH) 2 D 3 similar to our previous results (31) . However, 1,25-(OH) 2 D 3 given to normal rats as a single injection ip (20) or as a continuous dose by osmotic minipumps for 7 days resulted in a decrease in serum PTH and PTH mRNA levels (Fig. 1B) . It is not known what prevents the parathyroid cell from responding to the high levels of endogenous 1,25-(OH) 2 D 3 in the situation of hypocalcemia (30) . Calreticulin has been shown to inhibit the binding of sterol hormone receptors to their DNA responsive elements and prevent their action on their target genes. We therefore studied whether calreticulin was involved in the paradoxical increase in PTH mRNA by a low serum calcium despite the high levels of 1,25-(OH) 2 D 3 .
We studied the levels of calreticulin protein in parathyroid protein extracts from rats fed a normal or a low-calcium diet. A Western blot of nuclear and cytoplasmic proteins showed that in the nuclear fraction of the parathyroids of rats fed a low-calcium diet, there was a 2-fold increase in calreticulin level (Fig. 2) . There was no change in the cytoplasmic calreticulin in these rats. Similar results were obtained in two repeat ex-periments of different parathyroid protein preparations. Other tissues, such as liver, kidney, and brain showed no differences in calreticulin concentration in their nuclear fractions between control and hypocalcemic rats (not shown). Because of this increase in calreticulin concentration in the nuclear fraction of the parathyroids of hypocalcemic rats, we studied whether calreticulin affected the binding of the VDR to the PTH-VDRE.
Calreticulin Prevents Binding of the VDR-RXR␤ Heterodimer to the PTH VDRE Oligonucleotide
The VDR binds as a heterodimer with the RXR␤ to VDREs (10) . We therefore studied the effect of calreticulin on VDR-RXR␤ heterodimer binding to the VDRE of the cPTH promoter. In gel shift assays VDR and RXR␤ bound an oligonucleotide corresponding to the chicken VDRE (cVDRE) (Fig. 3 ) or rat VDRE (not shown) forming two complexes (Fig. 3) . VDR added to the cVDRE displayed binding (not shown) that was enhanced when the VDR was added together with RXR␤ (Fig. 3) . Surprisingly, RXR␤ alone also bound the VDRE. MacDonald et al. (12) showed that when 1,25-(OH) 2 D 3 was added to bovine parathyroid cells in primary culture, there was an additive effect of 9-cisretinoic acid to decrease PTH mRNA levels, which would be compatible with the enhanced binding of the combined VDR and RXR␤ to the cVDRE. The binding of the VDR-RXR␤ heterodimer to the cPTH-VDRE was inhibited by pure calreticulin in a dose-dependent manner (Fig. 3) . Calreticulin has three distinct structural domains, referred to as the N, P, and C domains (5). Burns et al. (5) showed that calreticulin prevented the glucocorticoid receptor binding to the glucocorticoid response element, and that this was mediated by the N domain and not the P domain of calreticulin. The C domain of calreticulin led to enhanced binding of the glucocorticoid receptor to the glucocorticoid response element (5) and the reason for that finding was not clear. In the present study, the addition of both the glutathione-S-transferase-N (GST-N) or GST-P fusion proteins (Fig. 3) or the GST protein (not shown) did not affect the binding of VDR-RXR␤ to the cVDRE oligonucleotide in mobility shift assays (Fig. 3) . The reason why both the N and the P domains of the calreticulin protein did not inhibit binding of the VDR-RXR␤ to the VDRE while the full-length calreticulin did inhibit binding is not clear. It may be because of S-S bridges or folding differences between the full-length calreticulin and its separate domains. Our results, therefore, do not allow us to draw a conclusion as to which domains in calreticulin interact with the VDR-RXR␤ complex.
We have shown that in vitro calreticulin interferes with the binding of the VDR-RXR␤ heterodimer to the VDRE oligonucleotide. A similar effect had been shown for the osteopontin gene shown by Wheeler et al. (9) who demonstrated that calreticulin prevented binding of the VDR-RXR heterodimer to the mouse osteopontin VDRE. Together with the present results, this shows that calreticulin inhibits DNA binding by the VDR in vitro. This effect may be due to binding of the calreticulin protein to the KXFF(K/R)R-like motif present in the DNA-binding domain of the receptor. This is the first demonstration that calreticulin can interfere with a down-regulatory effect of a sterol hormone on gene transcription. To determine a functional role for the effect of calreticulin on the response of the PTH promoter to 1,25-(OH) 2 (Fig. 4, A and C) and (10) . Overexpression of calreticulin, by using a sense orientation expression vector cotransfected with the A, PTH mRNA levels are increased by dietary hypocalcemia. Rats were maintained on a control diet or a low-calcium diet for 2 weeks after weaning. RNA was run on gels for Northern blots, and each lane represents thyroparathyroid RNA from a single rat. Hybridization was performed for PTH mRNA and 18S RNA as a control gene. B, PTH mRNA levels are decreased by 1,25-(OH) 2 D 3 . 1,25-(OH) 2 D 3 was given to normal rats by constant infusion by minipumps (50 pmol/day) for 7 days. PTH mRNA is shown, and the ethidium bromidestained membrane shows the 28S and 18S rRNA. Each lane represents thyroparathyroid RNA from a single rat. cPTH gene promoter-CAT construct, completely abolished the effect of 1,25-(OH) 2 D 3 on the PTH promoter (Fig. 4, B and C) . Cotransfection of the VDRE-CAT plasmid with a plasmid transcribing antisense calreticulin had no effect on the down-regulation of CAT transcription by 1,25-(OH) 2 D 3 (Fig. 4, B and C) . Similar results were obtained with the rat PTH VDRE (not shown). In all experiments, expression of a cotransfected cytomegalovirus (CMV)-␤-galactosidase plasmid was used as a control, and the results were normalized for ␤-galactosidase expression (Fig. 4) . To verify that the calreticulin cDNA was being expressed, a portion of the RNA from the transfected cells was analyzed by Northern blots. A calreticulin transcript of the correct size was easily detectable in cells with the overexpressed calreticulin plasmids, whereas it was undetectable in nontransfected cells (not shown). These results show that overexpression of calreticulin prevents the effect of 1,25-(OH) 2 D 3 to down-regulate CAT expression from a PTH-VDRE promoter. This is the first demonstration that calreticulin can prevent a down-regulatory effect of 1,25-(OH) 2 D 3 . It has been shown that calreticulin prevents the up-regulation by 1,25-(OH) 2 D 3 of the osteopontin gene transcription (9). Calreticulin's effect on the VDRE has been shown to be specific to the VDRE as it had no effect on the transcription of other promoter elements, such as the cAMP response element (9) . There are other examples in which calreticulin overexpression has been shown to inhibit a biological effect, such as the decreased expression of dexamethazone-sensitive cytochrome P450 protein and mRNA (5) . In addition, the overexpression of calreticulin and androgen receptor in Vero fibroblasts transfected with the androgen-responsive element-CAT construct, inhibited CAT activity induced by androgens (6) . The present results, therefore, support the notion that calreticulin can modify the action of sterol hormones on their target genes.
The effect of hypocalcemia to increase PTH mRNA levels in vivo is mainly posttranscriptional (31) , while the effect of 1,25-(OH) 2 D 3 is transcriptional (20) . Therefore, there must be a mechanism whereby the effect of hypocalcemia dominates over that of 1,25-(OH) 2 D 3 . Hypocalcemic rats have an increase in their PTH mRNA levels despite increased levels of 1,25-(OH) 2 D 3 that would have been expected to decrease PTH gene transcription. This paradox implies that there is a factor that prevents the effect of 1,25-(OH) 2 D 3 on the PTH gene. It is possible that calreticulin might be that factor. In the present study rats with hypocalcemia had an increased calreticulin concentration in the nuclear fraction of their parathyroids. This result is given a functional relevance by the findings in vitro in the present studies in which calreticulin prevented binding of the VDR-RXR␤ to the PTH-VDRE and where cotransfected sense calreticulin prevented the effect of 1,25-(OH) 2 D 3 to decrease VDRE-CAT transcription.
Many patients with chronic renal failure treated by chronic dialysis do not respond as expected to administration of 1,25-(OH) 2 D 3 (24) . In some patients this may be related to monoclonal replication of the parathyroids (29) or down-regulation of the VDR (25) , but this certainly does not apply to all such resistant patients. It is possible that in this subset of patients there is an increase in the calreticulin protein in their para- Western blot for calreticulin protein in rat parathyroids fed a normal or a low-calcium diet. Calreticulin protein was increased in the nuclear fraction (N) of hypocalcemic rats compared with control rats, but there was no change in calreticulin protein in the cytoplasmic fraction (C) of these rats. Fig. 3 . Calreticulin Inhibits Binding of the VDR-RXR␤ Heterodimer to the cVDRE Oligonucleotide VDR-RXR␤ was incubated without or with increasing amounts of intact calreticulin or the calreticulin N and P domains linked to GST after which the cVDRE probe was added. VDR-RXR␤ formed a complex with the cVDRE resulting in two bands indicated by the arrows. Added calreticulin, in increasing concentrations, inhibited the binding of the heterodimer to the cVDRE. Addition of GST-N domain of calreticulin or GST-P domain of calreticulin did not affect the binding. thyroids. The model used in the present study was secondary hyperparathyroidism due to hypocalcemia. This model simulates many of the features of secondary hyperparathyroidism of renal failure such as increased levels of PTH mRNA and serum PTH (30) as well as increased parathyroid cell proliferation (32) . In addition, the high levels of serum 1,25-(OH) 2 D 3 provide an opportunity to understand the resistance of the parathyroid to 1,25-(OH) 2 
MATERIALS AND METHODS
Animals
Weanling male Hebrew University strain rats were maintained on either a normal calcium (0.6%) diet or a low-calcium (0.02%) (ϪCa) diet (Teklad, Madison, WI) for 2 weeks. For the experiment with 1,25-(OH) 2 D 3 , rats of 150 g body weight were implanted with osmotic minipumps sc and received 1,25-(OH) 2 D 3 (50 pmol/day) or propylene glycol vehicle for 7 days. The thyroparathyroid tissue was removed under pentobarbital anesthesia and blood samples were taken for serum calcium and 1,25-(OH) 2 D 3 . All animal studies were conducted in accord with the principles and procedures outlined in the "Guidelines for Care and Use of Experimental Animals." For RNA extractions, thyroparathyroid tissue from individual rats was frozen in liquid nitrogen and stored at Ϫ70 C until analysis. RNA was extracted from the thyroparathyroids of each rat and analyzed by Northern blots for PTH mRNA and 18S ribosomal RNA as previously described (33) . For protein extraction, pooled microdissected parathyroids from 10 rats in each group, or other tissues from individual rats, were removed, and proteins from the nuclear and cytoplasmic fractions were extracted immediately by the method of Dignam et al. (34) .
Western Blot Analysis
Forty micrograms of the nuclear and cytosolic extracts were run on 10% SDS-polyacrylamide gel. The gels were transferred to nitrocellulose membrane and incubated with polyclonal goat anticalreticulin as first antibody (dilution of 1:300 in 1% BSA-1ϫ PBS) and then with horseradish peroxidaserec Protein G (Zymed Laboratories, South San Francisco, CA) as second antibody. The peroxidase reaction was developed using an ECL detection system (New England Biolabs, Beverly, MA).
DNA Mobility Shift Assay
Recombinant human (h) VDR and hRXR␤ were diluted 1:10 in ice-cold KTEDG buffer (400 mM KCl, 20 mM Tris, pH 7.5, 1 mM EDTA, 2 mM EDTA, 10% glycerol, 2 mM dithiothreitol), 1.6 l of the diluted proteins were used in 1ϫ binding buffer (100 mM KCl, 20 mM Tris, pH 7.5, 1.5 mM EDTA, 5% glycerol, 0.1% NP 40, 2 mM dithiothreitol), at a final volume of 20 l, which included 1 g deoxyinosinic-deoxycytidylic acid and the endlabeled VDRE DNA fragment probe (30,000 cpm). The reaction was incubated on ice for 1 h, loaded on a cooled prerun 5% nondenaturating polyacrylamide gel and run for 3 h in 0.5ϫ Tris-borate-EDTA buffer at 4 C. The gels were dried and exposed to x-ray film. The chicken cPTH VDRE (bold letters) consisted of 5Ј-gatcGGAAGCTTACATGAGGGTCAGGAGGGTGTGCCT-GCAGG-3Ј 3 Ј -CCTTCGAATGTACTCCCAGTCCTCCCACACGGACGTCCctag-5Ј
and was end-labeled with Klenow large-fragment enzyme using [␣-32 P[␤]dGTP. When the binding of the VDR-RXR␤ heterodimer to the VDRE was performed with increasing concentrations of calreticulin and its N and P domains or the GST protein, they were incubated at 4 C for 15 min before addition of the VDRE probe.
Plasmid Constructions
The cPTH promoter sequence, Ϫ55 to ϩ20 was synthesized by PCR and ligated into a commercially available p-CAT expression vector (Promega, Madison WI) using the SalI and XbaI restriction sites present in the multiple cloning site. An oligonucleotide containing the cPTH VDRE, GGGTCA GGA GGGTGT, was placed upstream from the cPTH promoter using the HindIII and SalI sites that were available. The calreticulin expression plasmid in the sense orientation was prepared by subcloning the XhoI-SmaI fragment of the pSVL-CRT plasmid (5) into pMCC-ZP plasmid containing a CMV promoter. The calreticulin expression plasmid in the antisense orientation was prepared as described (5) . Plasmids that expressed either the sense or antisense transcripts for the calreticulin gene were synthesized as described previously (5).
Transfection Studies
Opossum kidney (OK) cells were cotransfected by the method of lipofection (35) with the cPTH VDRE-CAT plasmid (2.5 g), CMV-␤-galactosidase (1 g) plasmid, and either the sense or antisense plasmid for calreticulin (1 g). Analysis of CAT and ␤-galactosidase gene transcripts after treatment with hormone (1 ϫ 10 Ϫ8 M) for 24 h were quantified by ribonuclease protection assay using a commercially available kit (Ambion, Austin TX). Total RNA from OK cells transfected with the cPTH-CAT and CMV-␤-galactosidase plasmid constructs was prepared by extraction with phenol-guanidinium thiocyanate. The RNA extracts were incubated with RNasefree DNase I (GIBCO-BRL, Bethesda MD) for 5 min at room temperature and ethanol precipitated. The RNA pellets were incubated with 32 P-labeled RNA probes (158 bases for CAT and 370 bases for ␤-galactosidase) in 20 l of buffer containing 80% formamide, 100 mM sodium citrate, pH 6.4, 300 mM sodium acetate, pH 6.4, and 1 mM EDTA, overnight at 43 C. The hybridization mixtures were digested with a combination of RNase A and RNase T1 at 37 C for 30 min. The protected RNA hybrids were precipitated with propanol-guanidinium thiocyanate and separated on 6% nondenaturing polyacrylamide gels. The gels were dried and exposed to x-ray film for 6 h at Ϫ80 C. The resulting autoradiograms were quantified by densitometric scanning, and values for the CAT gene transcripts were normalized with respect to the values for ␤-galactosidase gene transcripts. To verify that the calreticulin genes were being expressed in the experiments where calreticulin expression vectors were used, a portion of the RNA from the transfected cells was analyzed by Northern blots. In all cases a calreticulin transcript of the correct size was observed.
